Member Info for MarcEtMaker

Someone is loading up and hoovering up these sells

Why would anyone be selling now. Confirmation of India progress plus additional schools. The sells were picked up by sticky buyers on this pullback which will make this rise quickly.

Fantastic - always great exposure, which they were lacking as already significantly undervalued prior to this update. Lots of upside

Ruth March, senior vice-president of precision medicine at AstraZeneca, said the development of the serology ELISA was an example of AstraZeneca's "comprehensive response" to the Covid-19 pandemic.

"This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations."

Think we NSCI are onto a winner here will quoted well suited for large scale deployment. With a tiny mcap this is going to blow.

Can’t see this stopping to be honest, and most certainly not a pullback that far. This will keep going for a couple of days in my opinion before the pullback. Any selling will be mopped up.

UT was 146

Have a mcap of 20m and ha e struck a deal with one of the biggest phamas to commercialise with only paying a royalty. No brainer

Will finish on a daily high for sure

Will be paying 25 already

Close above 135 IMO

Agree

Great support this morning at the 22/23 p. Can see 40p here very soon. Gl all

This is firmly in control of the bulls. Super hammer finish today and Monday will be fireworks.

Investment summary: The Shield-led launch of Accrufer was always the best option, in our opinion. Although the fundraise was dilutive for shareholders, they were all invited to participate. Now that the period of uncertainty is over, coupled with the listing on the OTCQX market in the US to raise awareness and improve liquidity, we are starting to see a recovery in the shares. The actual launch of Accrufer in June will be the next catalyst to narrow the valuation disconnect .

Valuation: DCF-modelling each of the three main income streams – the US, Europe and China – generates an NPV, which, summed together, gives an EV for the group of $852m/£608m, or 281p per share. The current share price is clearly applying a very heavy discount for the execution risk associated with Accrufer.

All buys today except one. When this moves it will fly.

Can see another good day coming. Mostly all buys on Friday even though the red prints. I was quoted 4.99 to buy from lunchtime.

Looking very strong off the floor. This will recover well now the world is opening up. This was 50-60p pre-covid and I would argue now in a better position at only 5m mcap.

Broker target 250p. Not a bad Return from here.

It’s hard to say on fair value, but many multiples of current MCAP. They has 18m cash in January with total loss last year of 2.7m which includes start up and listing costs. Since then have secured sponsorship with subway and hyperx, with maiden sponsorship worth 1.2m per annum. Didn’t say what others worth. This is a huge growth sector which will attract higher p/e. I am interest to see the research note from McNulty which will hopefully be released soon.

This has been ranging for the last 7 months, with sellers into the rise (probably seed money). This is now drying up, allowing the SP to reflect the potential and already realised growth of the business. Even the last RNS stated the exposure has grown from 10k to 450k, including signing of high profile players and sponsorship deals. This IPO’d at 8p and the business has made huge strides since then. I think this will move quickly now to a fair value.